Own the gold standard ✨ in financial data & analytics

Subscribe for $2
Overview
Profile

InnoCare Pharma Company

9969.HK
KYG4783B1032
A2PVC2

Price

6.25
Today +/-
-0.01
Today %
-0.74 %
P

InnoCare Pharma stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the InnoCare Pharma stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the InnoCare Pharma stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the InnoCare Pharma stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze InnoCare Pharma's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

InnoCare Pharma Stock Price History

DateInnoCare Pharma Price
10/25/20246.25 undefined
10/24/20246.29 undefined
10/23/20246.41 undefined
10/22/20246.33 undefined
10/21/20246.40 undefined
10/18/20246.32 undefined
10/17/20245.90 undefined
10/16/20245.91 undefined
10/15/20245.85 undefined
10/14/20246.15 undefined
10/10/20246.28 undefined
10/9/20246.11 undefined
10/8/20246.20 undefined
10/7/20246.75 undefined
10/4/20246.21 undefined
10/3/20245.74 undefined
10/2/20246.06 undefined
9/30/20246.09 undefined
9/27/20245.48 undefined
9/26/20245.04 undefined

InnoCare Pharma Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into InnoCare Pharma, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by InnoCare Pharma from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects InnoCare Pharma’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of InnoCare Pharma. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into InnoCare Pharma’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing InnoCare Pharma’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on InnoCare Pharma’s growth potential.

InnoCare Pharma Revenue, EBIT and net profit per share

DateInnoCare Pharma RevenueInnoCare Pharma EBITInnoCare Pharma Net Income
2029e3.81 B undefined0 undefined0 undefined
2028e3.22 B undefined1.08 B undefined0 undefined
2027e2.55 B undefined763.49 M undefined0 undefined
2026e1.8 B undefined-397.79 M undefined90.88 M undefined
2025e1.36 B undefined-647.85 M undefined-408.96 M undefined
2024e962.8 M undefined-768.82 M undefined-643.73 M undefined
2023e740.15 M undefined-787.33 M undefined-747.23 M undefined
2022625.4 M undefined-730.9 M undefined-886.59 M undefined
20211.04 B undefined-165.81 M undefined-64.55 M undefined
20201.36 M undefined-494.15 M undefined-391.4 M undefined
20191.25 M undefined-2.22 B undefined-2.14 B undefined
20181.62 M undefined-564.43 M undefined-549.95 M undefined
2017102,000 undefined-340.25 M undefined-341.73 M undefined

InnoCare Pharma Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (B)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (B)DOCUMENTS
2017201820192020202120222023e2024e2025e2026e2027e2028e2029e
00001.040.630.740.961.361.82.553.223.81
----104,200.00-40.0818.4030.0041.7931.9641.6726.3918.18
-100.00100.00100.0093.6777.12-------
01119774820000000
-0.34-0.56-2.22-0.49-0.17-0.73-0.79-0.77-0.65-0.40.761.080
--56,400.00-222,400.00-49,400.00-15.82-116.80-106.35-79.83-47.43-22.0629.9233.60-
-341-549-2,141-391-64-886-747-643-40890000
-61.00289.98-81.74-83.631,284.38-15.69-13.92-36.55-122.06---
1111.761.761.480000000
-------------
Details

Keystats

ⓘ

Revenue and Growth

The InnoCare Pharma Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the InnoCare Pharma is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (B)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
201720182019202020212022
           
0.052.052.3746.299.05
00.040.040.1545.27127.82
5.8414.523.3951.8720.9116.8
0001.889.9265.32
0.843.2913.239.2354.0936.12
0.052.062.414.096.429.3
12.0817.96163.86330.42546.1696.45
1.161.161.161.16326.111.71
000062.2761.79
36.5836.9537.01111.84107.45273.14
3.133.133.133.123.123.12
0.8878.461.85.5115.0944.65
0.050.140.210.451.061.09
0.112.22.624.547.4810.39
           
33416.1319.3923.18
000.016.989.6312.08
-376.2-860.94-2,936.52-3,497.12-3,561.66-4,448.26
-9.83-37.33-71.5-376.3-465.76-36.31
-6.04-6.04-6.04-6.04-6.040
-0.39-0.9-33.15.67.6
2.962.198.216.984.6118.6
2.974.389.5426.3741.6768.07
20.351.1132.6347.22170.04663.73
0.080.060.01001.2
2.85.336.26.8320.3420.11
0.110.070.070.10.322.07
0.392.95.331.171.290.04
6.046.046.046.0400
0.4261.4157.39110.48153.7581.35
0.392.975.51.281.440.62
0.53.045.561.381.762.68
0.112.142.564.487.3510.28
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of InnoCare Pharma provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand InnoCare Pharma's financial health and stability.

Assets

InnoCare Pharma's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that InnoCare Pharma must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of InnoCare Pharma after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into InnoCare Pharma's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (B)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (B)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201720182019202020212022
-341-554-2,1500-64-886
35903667
000000
35591-125-249-409
0.290.481.9700.080.33
132023
000029-18
-49-17-79-297167-490
-1-20-45-228-171-370
25-88847-1,100-1,714-1,801
26-86892-871-1,542-1,431
000000
0.052.030.36-0.010.050.33
000.0102.532.92
0.032.10.362.242.543.09
-0.020.07-02.252.492.77
000000
01.210.350.521.340.88
000-526.45-4.15-860.91
000000

InnoCare Pharma stock margins

The InnoCare Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of InnoCare Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for InnoCare Pharma.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the InnoCare Pharma's sales revenue. A higher gross margin percentage indicates that the InnoCare Pharma retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the InnoCare Pharma's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the InnoCare Pharma's total revenue generated. When comparing the revenue margin year over year, investors can gauge the InnoCare Pharma's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the InnoCare Pharma. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the InnoCare Pharma's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

InnoCare Pharma Margin History

InnoCare Pharma Gross marginInnoCare Pharma Profit marginInnoCare Pharma EBIT marginInnoCare Pharma Profit margin
2029e77.07 %0 %0 %
2028e77.07 %33.6 %0 %
2027e77.07 %29.94 %0 %
2026e77.07 %-22.09 %5.05 %
2025e77.07 %-47.46 %-29.96 %
2024e77.07 %-79.85 %-66.86 %
2023e77.07 %-106.37 %-100.96 %
202277.07 %-116.87 %-141.76 %
202193.7 %-15.9 %-6.19 %
2020100 %-36,238.39 %-28,702.66 %
2019100 %-178,392.61 %-171,723.17 %
2018100 %-34,906 %-34,010.51 %
2017100 %-333,577.44 %-335,033.35 %

InnoCare Pharma Stock Sales Revenue, EBIT, Earnings per Share

The InnoCare Pharma earnings per share therefore indicates how much revenue InnoCare Pharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue InnoCare Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates InnoCare Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of InnoCare Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating InnoCare Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

InnoCare Pharma Revenue, EBIT and net profit per share

DateInnoCare Pharma Sales per ShareInnoCare Pharma EBIT per shareInnoCare Pharma Earnings per Share
2029e2.54 undefined0 undefined0 undefined
2028e2.15 undefined0 undefined0 undefined
2027e1.7 undefined0 undefined0 undefined
2026e1.2 undefined0 undefined0.06 undefined
2025e0.91 undefined0 undefined-0.27 undefined
2024e0.64 undefined0 undefined-0.43 undefined
2023e0.49 undefined0 undefined-0.5 undefined
20220.42 undefined-0.49 undefined-0.6 undefined
20210.59 undefined-0.09 undefined-0.04 undefined
20200 undefined-0.28 undefined-0.22 undefined
20190 undefined-2.22 undefined-2.14 undefined
20180 undefined-0.56 undefined-0.55 undefined
20170 undefined-0.34 undefined-0.34 undefined

InnoCare Pharma business model

InnoCare Pharma Ltd is a biopharmaceutical company based in China, focused on researching, developing, and marketing novel therapies for the treatment of severe diseases. The company was founded in 2015 by Dr. Jasmine Cui with the goal of developing innovative therapies that improve patients' lives and advance medical progress. InnoCare has become a key player in the biopharmaceutical industry in China since its establishment and has been listed on the Hong Kong Stock Exchange since 2019. The company has a diversified business model, with a focus on research and development, product marketing and licensing, and collaboration with other companies to develop new therapies. InnoCare specializes in various therapeutic areas, including oncology, immunology, neurology, and dermatology. The company has a wide portfolio of products in clinical development, including small molecules and antibodies that aim to meet unmet medical needs of patients. One of InnoCare's most promising products is ICP-192, a small molecule that can be used to treat various types of cancer. ICP-192, developed by InnoCare itself, is currently in phase III clinical trials. Other important products of InnoCare include ICP-151, a small molecule for treating chronic respiratory diseases, ICP-105, an antibody for treating severe autoimmune diseases, and ICP-601, a small molecule for treating skin inflammation and psoriasis. InnoCare has also entered into several strategic partnerships to expand its growth opportunities and product portfolio. One of these partnerships is collaboration with Roche for the development of ICP-192. InnoCare has also entered into a cooperation agreement with Sanofi for the development of ICP-105 and a licensing agreement with Novartis for the marketing of ICP-151 in China. InnoCare Pharma Ltd is an emerging company in the biopharmaceutical industry, focusing on the development and marketing of innovative therapies for the treatment of severe diseases. The company has a diversified business model based on research and development, product marketing and licensing, and collaboration with other companies for the development of new therapies. With a wide portfolio of products in clinical development and strategic partnerships with renowned companies, InnoCare has great potential for further growth and success in the future. InnoCare Pharma is one of the most popular companies on Eulerpool.com.

InnoCare Pharma SWOT Analysis

Strengths

InnoCare Pharma Ltd possesses several significant strengths that contribute to its success in the market:

  • Strong Research and Development capabilities, allowing the company to stay at the forefront of innovation.
  • Extensive portfolio of patented products, providing a competitive advantage and ensuring revenue stability.
  • Well-established relationships with key healthcare professionals, facilitating effective distribution and market reach.
  • Strong financial position and solid profitability, enabling the company to invest in further growth opportunities.

Weaknesses

Despite its strong position, InnoCare Pharma Ltd has certain weaknesses that can hinder its growth and performance:

  • Relatively small scale compared to some competitors, which limits the company's resources and market presence.
  • Dependence on a limited number of key products, leaving it vulnerable to potential market changes or patent expirations.
  • Limited geographical diversification, making it susceptible to regional economic or regulatory fluctuations.

Opportunities

InnoCare Pharma Ltd can leverage several opportunities to expand its market share and enhance its position:

  • Increasing adoption of innovative healthcare solutions, creating a growing demand for cutting-edge pharmaceutical products.
  • Emerging markets offer untapped potential for expansion, as they experience economic growth and rising healthcare needs.
  • Strategic partnerships and collaborations with research institutes or other pharmaceutical companies can drive innovation and extend product offerings.
  • Expanding product portfolio through acquisitions or licensing agreements, addressing new therapeutic areas and diversifying revenue streams.

Threats

InnoCare Pharma Ltd faces several threats that may impact its growth and competitive position:

  • Intense competition within the pharmaceutical industry, requiring constant innovation and pricing pressures.
  • Regulatory challenges and stringent approval processes can delay product launches and increase costs.
  • Potential patent infringements or generic competition that may erode market share and profitability.
  • Political and economic uncertainties, such as changing healthcare policies or financial crises, affecting the overall market conditions.

InnoCare Pharma Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

InnoCare Pharma historical P/E ratio, EBIT multiple, and P/S ratio

InnoCare Pharma shares outstanding

The number of shares was InnoCare Pharma in 2023 — This indicates how many shares 1.478 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue InnoCare Pharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates InnoCare Pharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of InnoCare Pharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating InnoCare Pharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for InnoCare Pharma.

InnoCare Pharma shareholders

%
Name
Stocks
Change
Date
1.33363 % Wanjia Asset Management Co., Ltd.20,000,000012/31/2023
1.27699 % Penghua Fund Management Co., Ltd.19,150,5942,623,41612/31/2023
0.59850 % Guangzhou High-tech Zone Technology Holdings Group Co., Ltd.8,975,521012/31/2023
0.59346 % China Fund Management Co., Ltd.8,900,000350,00012/31/2023
0.53399 % Bank of China Investment Management Co., Ltd.8,008,154-241,42412/31/2023
0.23962 % JPMorgan Asset Management (China) Company Limited.3,593,4691,586,92012/31/2023
0.12713 % China Asset Management Co., Ltd.1,906,589-1,306,58012/31/2023
0.08202 % Morgan Stanley Investment Management (China) Company Limited.1,229,987-522,73012/31/2023
0.06764 % Guotai Asset Management Co., Ltd.1,014,363-1,375,5606/30/2023
0.06705 % HuaAn Fund Management Co., Ltd.1,005,454-1,849,2096/30/2023
1
2
3
4
5
...
6

InnoCare Pharma Executives and Management Board

Dr. Jisong Cui59
InnoCare Pharma Executive Chairman of the Board, Chief Executive Officer (since 2015)
Compensation 29.41 M
Dr. Renbin Zhao53
InnoCare Pharma Executive Director (since 2015)
Compensation 2.04 M
Ms. Lan Hu50
InnoCare Pharma Non-Executive Independent Director
Compensation 366,000
Dr. Kaixian Chen76
InnoCare Pharma Non-Executive Independent Director
Compensation 360,000
Mr. Shaojing Tong50
InnoCare Pharma Chief Financial Officer
1
2
3

InnoCare Pharma Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Biogen Stock
Biogen
SupplierCustomer-0,100,140,390,790,870,68
Genetron Holdings ADR Stock
Genetron Holdings ADR
SupplierCustomer-0,460,760,430,940,91-
WuXi AppTec Co H Stock
WuXi AppTec Co H
SupplierCustomer-0,530,870,400,900,870,78
Incyte Stock
Incyte
SupplierCustomer-0,770,71-0,11-0,620,26-0,27
1

Most common questions regarding InnoCare Pharma

What values and corporate philosophy does InnoCare Pharma represent?

InnoCare Pharma Ltd represents a set of core values and a corporate philosophy that guides its operations. The company is committed to innovation, aiming to develop and deliver breakthrough therapeutics to patients in need. InnoCare Pharma values integrity and transparency, fostering strong relationships with stakeholders, including patients, healthcare professionals, and investors. The company prioritizes quality and excellence in all aspects of its business, ensuring the highest standard of research, development, and manufacturing processes. InnoCare Pharma also believes in collaboration and teamwork, working closely with partners to achieve its goals.

In which countries and regions is InnoCare Pharma primarily present?

InnoCare Pharma Ltd is primarily present in China, with its headquarters located in Beijing. The company focuses on research, development, and commercialization of innovative drugs to address unmet medical needs. With a strong emphasis on precision medicine, InnoCare Pharma aims to provide effective treatments for patients in China and globally. As a leading biopharmaceutical company, InnoCare Pharma has expanded its reach to international markets, ensuring its presence in various countries and regions worldwide.

What significant milestones has the company InnoCare Pharma achieved?

InnoCare Pharma Ltd has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in 2020, raising a substantial amount of funds to support its research and development initiatives. InnoCare Pharma Ltd also obtained regulatory approval for its leading drug candidate, ICP-192, for the treatment of various types of cancer. Furthermore, the company has entered into strategic partnerships and collaborations with renowned pharmaceutical companies, enabling it to expand its global reach and accelerate the development and commercialization of its pipeline products. These achievements demonstrate InnoCare Pharma Ltd's commitment to advancing innovative therapies and its potential for growth in the biopharmaceutical industry.

What is the history and background of the company InnoCare Pharma?

InnoCare Pharma Ltd is a biopharmaceutical company founded in 2015 in Suzhou, China. The company focuses on the discovery, development, and commercialization of innovative and differentiated therapeutics for the treatment of cancer and autoimmune diseases. InnoCare Pharma Ltd has quickly established itself as a leading player in the biopharmaceutical industry. With a strong commitment to research and development, the company has built a diverse pipeline of potential drug candidates. InnoCare Pharma Ltd's dedication to improving patient outcomes and addressing unmet medical needs has propelled its growth and garnered recognition in the global healthcare community.

Who are the main competitors of InnoCare Pharma in the market?

The main competitors of InnoCare Pharma Ltd in the market include international pharmaceutical companies such as AstraZeneca, Pfizer, Novartis, and Roche. These companies are renowned for their strong presence in the pharmaceutical industry and their extensive product portfolios. InnoCare Pharma Ltd, an innovative biopharmaceutical company, strives to differentiate itself by focusing on developing and commercializing novel medicines targeting cancer and autoimmune diseases. As a dynamic player in the market, InnoCare Pharma Ltd aims to carve out a niche through its unique pipeline and therapeutic advancements, while continually competing with established industry leaders.

In which industries is InnoCare Pharma primarily active?

InnoCare Pharma Ltd primarily operates in the pharmaceutical industry.

What is the business model of InnoCare Pharma?

The business model of InnoCare Pharma Ltd revolves around the development and commercialization of innovative and targeted therapies for patients with various types of cancer. By leveraging its scientific expertise and strong research capabilities, InnoCare Pharma focuses on discovering and advancing breakthrough drug candidates, aiming to address unmet medical needs and improve the lives of patients. Through strategic collaborations and partnerships, the company is committed to accelerating the development and global commercialization of its proprietary medications. InnoCare Pharma's business model allows it to bring novel, safe, and effective treatments to market, ultimately contributing to the advancement of oncology care.

What is the P/E ratio of InnoCare Pharma 2024?

The InnoCare Pharma P/E ratio is -14.34.

What is the P/S ratio of InnoCare Pharma 2024?

The InnoCare Pharma P/S ratio is 9.59.

What is the Quality Investing of InnoCare Pharma?

The Quality Investing for InnoCare Pharma is 2/10.

What is the revenue of InnoCare Pharma 2024?

The expected InnoCare Pharma revenue is 962.8 M CNY.

How high is the profit of InnoCare Pharma 2024?

The expected InnoCare Pharma profit is -643.73 M CNY.

What is the business model of InnoCare Pharma

InnoCare Pharma Ltd is a Chinese biopharmaceutical company that specializes in researching and developing novel drugs. The company focuses on the treatment of oncological, inflammatory, and metabolic diseases. Its business model involves discovering new drug candidates, conducting clinical trials, and marketing pharmaceutical products. InnoCare Pharma Ltd has experience in collaborating with international partners and has built a wide network of scientists and research institutions to accelerate the development of innovative therapies. The company's main divisions are research and development, production, and distribution. The research and development segment involves searching for new drug candidates for various diseases and conducting clinical trials to evaluate their effectiveness and safety. The production department is responsible for manufacturing and selling drugs based on the research and development findings. InnoCare Pharma Ltd is dedicated to developing novel therapies for cancer, inflammation, and metabolic disorders. It produces these therapies in partnerships with selected pharmaceutical manufacturers and sells them in the Chinese market, working with chosen distribution partners to reach patients. The company's important product portfolio includes the Janus Kinase (JAK) inhibitor candidate, intended for treating inflammatory conditions such as rheumatoid arthritis. Currently, the JAK candidate is in Phase II of development. Another significant drug candidate from InnoCare Pharma Ltd is ICP-192, also known as an ATR inhibitor. This drug is intended for cancer treatment and is currently in Phase I of clinical development. InnoCare Pharma Ltd stands out from other Chinese pharmaceutical companies due to its innovative approach to drug development. The company collaborates closely with research institutions in the USA, Europe, and Asia to improve the efficacy and safety of its drugs. In summary, the business model of InnoCare Pharma Ltd is based on the development of new and innovative drugs. The company leverages partnerships and networking opportunities with other research groups to accelerate research and development processes. Manufacturing and selling the medications occur in collaboration with other companies in the pharmaceutical industry. The portfolio focuses on innovative therapies for cancer, inflammation, and metabolic disorders. The company's future prospects are promising as the demand for new and innovative drugs continues to rise in the Chinese market.

What is the InnoCare Pharma dividend?

InnoCare Pharma pays a dividend of 0 CNY distributed over payouts per year.

How often does InnoCare Pharma pay dividends?

The dividend cannot currently be calculated for InnoCare Pharma or the company does not pay out a dividend.

What is the InnoCare Pharma ISIN?

The ISIN of InnoCare Pharma is KYG4783B1032.

What is the InnoCare Pharma WKN?

The WKN of InnoCare Pharma is A2PVC2.

What is the InnoCare Pharma ticker?

The ticker of InnoCare Pharma is 9969.HK.

How much dividend does InnoCare Pharma pay?

Over the past 12 months, InnoCare Pharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, InnoCare Pharma is expected to pay a dividend of 0 CNY.

What is the dividend yield of InnoCare Pharma?

The current dividend yield of InnoCare Pharma is .

When does InnoCare Pharma pay dividends?

InnoCare Pharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of InnoCare Pharma?

InnoCare Pharma paid dividends every year for the past 0 years.

What is the dividend of InnoCare Pharma?

For the upcoming 12 months, dividends amounting to 0 CNY are expected. This corresponds to a dividend yield of 0 %.

In which sector is InnoCare Pharma located?

InnoCare Pharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von InnoCare Pharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of InnoCare Pharma from 10/25/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 10/25/2024.

When did InnoCare Pharma pay the last dividend?

The last dividend was paid out on 10/25/2024.

What was the dividend of InnoCare Pharma in the year 2023?

In the year 2023, InnoCare Pharma distributed 0 CNY as dividends.

In which currency does InnoCare Pharma pay out the dividend?

The dividends of InnoCare Pharma are distributed in CNY.

All fundamentals about InnoCare Pharma

Our stock analysis for InnoCare Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of InnoCare Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.